-
1.发明授权Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用
公开(公告)号：US6054567A
公开(公告)日：2000-04-25
申请号：US840316
申请日：1997-04-11
IPC分类号： G01N33/576 , A61K38/00 , A61K39/00 , A61K39/29 , A61P1/16 , A61P31/20 , C07K14/08 , C07K16/10 , C12N5/10 , C12N15/09 , C12N15/51 , C12P21/02 , C12N15/11 , C12N15/00 , C12N15/63 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/28122 , G01N2333/08
摘要： The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 本发明涉及在真核表达系统中来自巴基斯坦（SAR-55）的乙型肝炎病毒株的开放阅读框2（ORF-2）蛋白的表达。 表达的蛋白质可以用作诊断免疫测定中的抗原和/或作为免疫原或疫苗以防止乙型肝炎的感染。
-
2.发明授权Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06787145B1
公开(公告)日：2004-09-07
申请号：US09724475
申请日：2000-11-28
IPC分类号： A61K3929
CPC分类号： C12N15/1131 , A61K38/00 , A61K39/00 , C07H21/00 , C07K14/005 , C12N7/00 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28122 , C12N2770/28123 , Y10S436/82 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
3.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06696242B1
公开(公告)日：2004-02-24
申请号：US08470246
申请日：1995-06-06
IPC分类号： C12Q170
CPC分类号： C12N15/1131 , A61K38/00 , A61K39/00 , C07H21/00 , C07K14/005 , C12N7/00 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28122 , C12N2770/28123 , Y10S436/82 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
4.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 有权巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06458562B1
公开(公告)日：2002-10-01
申请号：US09402776
申请日：2000-02-22
IPC分类号： C12N1551
CPC分类号： C07K14/005 , C12N2770/28122 , Y10S977/804
摘要： The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 本发明涉及在真核表达系统中来自巴基斯坦（SAR-55）的乙型肝炎病毒株的开放阅读框2（ORF-2）蛋白的表达。 表达的蛋白质可以用作诊断免疫测定中的抗原和/或作为免疫原或疫苗以防止乙型肝炎的感染。
-
公开(公告)号：US06287759B1
公开(公告)日：2001-09-11
申请号：US08471971
申请日：1995-06-06
IPC分类号： C12Q170
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07H21/00 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , Y10S977/802 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
-
6.发明授权Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用公开(公告)号：US06207416B1
公开(公告)日：2001-03-27
申请号：US08809523
申请日：1997-05-28
IPC分类号： C12N1551
CPC分类号： C07H21/00 , A61K38/00 , A61K39/00 , C07K14/005 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。
-
公开(公告)号：US06706873B1
公开(公告)日：2004-03-16
申请号：US08316765
申请日：1994-10-03
IPC分类号： C07H2104
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07H21/00 , C12N7/00 , C12N15/1131 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28021 , C12N2770/28022 , C12N2770/28122 , C12N2770/28123 , Y10S977/802 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
-
公开(公告)号：US6146643A
公开(公告)日：2000-11-14
申请号：US473185
申请日：1995-06-07
CPC分类号： C07K14/005 , C12N7/00 , A61K39/00 , C12N2770/32422 , C12N2770/32434 , C12N2770/32461 , Y10S530/825
摘要： The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
摘要翻译： 本发明一般涉及猿猴甲型肝炎病毒分离物AGM-27的基本上纯的制剂; 猿猴甲型肝炎病毒分离株AGM-27的基因组DNA基本上纯的制剂; 包含猿猴甲型肝炎病毒分离物AGM-27的药物组合物; 预防动物中甲型肝炎的方法; 和包含猿猴甲型肝炎病毒分离物AGM-27的疫苗。
-
公开(公告)号：US20110243840A1
公开(公告)日：2011-10-06
申请号：US13038613
申请日：2011-03-02
IPC分类号： A61K51/00 , C07K16/08 , C07K16/46 , A61K39/395 , A61K49/16 , A61P31/20 , A61P37/04 , A61P43/00 , C12Q1/70
CPC分类号： C07K16/081 , A61K39/00 , A61K2039/505 , A61K2039/545 , C07K14/005 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2710/24122 , G01N33/56983 , G01N2333/07
摘要： The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和正痘病毒的单克隆抗体。 本发明提供了这样的抗体，这种抗体保留B5或A33结合能力的片段，完全人抗体保留B5或A33结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
公开(公告)号：US07846454B2
公开(公告)日：2010-12-07
申请号：US11784809
申请日：2007-04-09
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/525 , C07K2319/00 , C12N7/00 , C12N2770/24221 , C12N2770/24222
摘要： The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.
摘要翻译： 本发明公开了编码感染性丙型肝炎病毒的核酸序列，以及这些序列的使用以及由全部或部分序列编码的多肽在开发用于HCV的疫苗和诊断中的用途，以及用于鉴定的筛选测定 的HCV抗病毒剂。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.031 秒)
